{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:27Z","timestamp":1791397287477,"version":"4.3.3"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071552"],"award-info":[{"award-number":["82071552"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["JCTD-2021-06"],"award-info":[{"award-number":["JCTD-2021-06"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Cognitive impairment (CI) is a substantial contributor to the disability associated with Parkinson\u2019s disease (PD). We aimed to assess the clinical features and explore the underlying biomarkers as predictors of CI in patients with newly diagnosed PD (NDPD; less than 2 years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated the cognitive function status using the Montreal Cognitive Assessment (MoCA) and a battery of neuropsychological tests at baseline and subsequent annual follow-up for 5 years from the Parkinson\u2019s Progression Markers Initiative (PPMI) database. We assessed the baseline clinical features, apolipoprotein (<jats:italic>APO<\/jats:italic>) <jats:italic>E<\/jats:italic> status, \u03b2-glucocerebrosidase (<jats:italic>GBA<\/jats:italic>) mutation status, cerebrospinal fluid findings, and dopamine transporter imaging results. Using a diagnosis of CI (combined mild cognitive impairment and dementia) developed during the 5-year follow-up as outcome measures, we assessed the predictive values of baseline clinical variables and biomarkers. We also constructed a predictive model for the diagnosis of CI using logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 409 patients with NDPD with 5-year follow-up were enrolled, 232 with normal cognitive function at baseline, and 94 patients developed CI during the 5-year follow-up. In multivariate analyses, age, current diagnosis of hypertension, baseline MoCA scores, Movement disorder society Unified PD Rating Scale part III (MDS-UPDRS III) scores, and <jats:italic>APOE<\/jats:italic> status were associated with the development of CI. Predictive accuracy of CI using age alone improved by the addition of clinical variables and biomarkers (current diagnosis of hypertension, baseline MoCA scores, and MDS-UPDRS III scores, <jats:italic>APOE<\/jats:italic> status; <jats:italic>AUC<\/jats:italic> 0.80 [95% <jats:italic>CI<\/jats:italic> 0.74\u20130.86] vs. 0.71 [0.64\u20130.77], <jats:italic>p<\/jats:italic>\u2009=\u20090.008). Cognitive domains that had higher frequencies of impairment were found in verbal memory (12.6 vs. 16.8%) and attention\/processing speed (12.7 vs. 16.9%), however, no significant difference in the prevalence of CI at annual follow-up was found during the 5-year follow-up in NDPD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In NDPD, the development of CI during the 5-year follow-up can be predicted with good accuracy using a model combining age, current diagnosis of hypertension, baseline MoCA scores, MDS-UPDRS III scores, and <jats:italic>APOE<\/jats:italic> status. Our study underscores the need for the earlier identification of CI in NDPD patients in our clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2023.1142558","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:51:59Z","timestamp":1678121519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictors of cognitive impairment in newly diagnosed Parkinson\u2019s disease with normal cognition at baseline: A 5-year cohort study"],"prefix":"10.3389","volume":"15","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaobo","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson's disease: a community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of type 2 diabetes in Parkinson's disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov. Disord."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201659","article-title":"Association between orthostatic hypotension and dementia in patients with Parkinson disease and multiple system atrophy","author":"Barrio","year":"2022","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41583-021-00542-9","article-title":"Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? Nature reviews","volume":"23","author":"Blesa","year":"2022","journal-title":"Neuroscience"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"703158","DOI":"10.3389\/fnagi.2021.703158","article-title":"Development and validation of a prognostic model for cognitive impairment in Parkinson's disease with REM sleep behavior disorder","volume":"13","author":"Chen","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","article-title":"Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture","volume":"53","author":"Chia","year":"2021","journal-title":"Nat. Genet."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson's disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","article-title":"The MoCA: well-suited screen for cognitive impairment in Parkinson disease","volume":"75","author":"Dalrymple-Alford","year":"2010","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11910-022-01226-2","article-title":"Polysomnographic predictors of sleep, motor, and cognitive dysfunction progression in Parkinson's disease","volume":"22","author":"Dijkstra","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1017\/neu.2019.28","article-title":"Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease","volume":"32","author":"D'souza","year":"2020","journal-title":"Acta Neuropsychiatr."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/mds.27803","article-title":"Classification of GBA variants and their effects in Synucleinopathies","volume":"34","author":"Gan-Or","year":"2019","journal-title":"Mov. Disord."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mds.27617","article-title":"Risk of Parkinson's disease dementia related to level I MDS PD-MCI","volume":"34","author":"Hoogland","year":"2019","journal-title":"Mov. Disord."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/mds.25748","article-title":"Predictors of cognitive impairment in an early stage Parkinson's disease cohort","volume":"29","author":"Hu","year":"2014","journal-title":"Mov. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","article-title":"Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts","volume":"34","author":"Iwaki","year":"2019","journal-title":"Mov. Disord."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/bs.irn.2016.12.001","article-title":"Cerebrospinal fluid biomarkers of cognitive decline in Parkinson's disease","volume":"132","author":"Johar","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2017.12.006","article-title":"Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: analysis of the PPMI cohort","volume":"47","author":"Jones","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3233\/JPD-212570","article-title":"Constipation is associated with development of cognitive impairment in de novo Parkinson's disease: a longitudinal analysis of two international cohorts","volume":"11","author":"Leta","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society task force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov. Disord."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's","volume":"80","author":"Liu","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","article-title":"CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson's disease","volume":"21","author":"Liu","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1474-4422(17)30122-9","article-title":"Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts","volume":"16","author":"Liu","year":"2017","journal-title":"Lancet. Neurol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson's disease","volume":"17","author":"Marinus","year":"2018","journal-title":"Lancet. Neurol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaneurol.2014.1455","article-title":"APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease","volume":"71","author":"Mata","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De novo Parkinson cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00415-020-10189-8","article-title":"Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study","volume":"268","author":"Nicoletti","year":"2021","journal-title":"J. Neurol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.25170","article-title":"Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies","volume":"83","author":"Norcliffe-Kaufmann","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0000000000003634","article-title":"Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study","volume":"88","author":"Pedersen","year":"2017","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00702-016-1622-6","article-title":"Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study","volume":"123","author":"Pellecchia","year":"2016","journal-title":"J. Neural Transm. (Vienna, Austria: 1996)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41531-020-00121-2","article-title":"Multivariate prediction of dementia in Parkinson's disease","volume":"6","author":"Phongpreecha","year":"2020","journal-title":"NPJ Parkinson's Dis."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac414","article-title":"Association between the LRP1B and APOE loci in the development of Parkinson's disease dementia. Brain: a","author":"Real","year":"2022","journal-title":"J. Neurol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet. Neurol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.29209","article-title":"Uric acid in Parkinson's disease: what is the connection?","volume":"37","author":"Seifar","year":"2022","journal-title":"Mov. Disord."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov. Disord."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mds.28342","article-title":"Genome-wide association studies of cognitive and motor progression in Parkinson's disease","volume":"36","author":"Tan","year":"2021","journal-title":"Mov. Disord."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12031-015-0647-x","article-title":"CSF \u03b2-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease","volume":"58","author":"Terrelonge","year":"2016","journal-title":"J. Mol. Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1142558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:52:03Z","timestamp":1678121523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1142558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":41,"alternative-id":["10.3389\/fnagi.2023.1142558"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2023.1142558","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"1142558"}}